Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 06
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118
+1.4%
|
$16,166
$137.12 P/Share
|
|
Jul 06
2021
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90
+0.31%
|
$12,330
$137.12 P/Share
|
|
Jul 06
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66
+0.04%
|
$9,042
$137.12 P/Share
|
|
Jul 06
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100
+0.28%
|
$13,700
$137.12 P/Share
|
|
Jul 06
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.17%
|
$21,098
$137.12 P/Share
|
|
Jul 06
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
113
+0.35%
|
$15,481
$137.12 P/Share
|
|
Jun 10
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
23,540
-23.24%
|
$5,061,100
$215.0 P/Share
|
|
Jun 09
2021
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
814
+1.1%
|
-
|
|
Jun 09
2021
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
814
+10.81%
|
-
|
|
Jun 09
2021
|
Jeryl L Hilleman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,270
-30.14%
|
$266,700
$210.01 P/Share
|
|
Jun 09
2021
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
814
+16.19%
|
-
|
|
Jun 09
2021
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
814
+0.5%
|
-
|
|
Jun 09
2021
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Direct |
814
+4.95%
|
-
|
|
Jun 09
2021
|
Sherilyn S Mc Coy Director |
BUY
Grant, award, or other acquisition
|
Direct |
814
+10.81%
|
-
|
|
Jun 07
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$204,000
$204.55 P/Share
|
|
Jun 07
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.35%
|
$31,000
$31.45 P/Share
|
|
May 27
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,833
-5.93%
|
$366,600
$200.0 P/Share
|
|
May 27
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+5.6%
|
$86,151
$47.56 P/Share
|
|
May 12
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,943
-6.27%
|
$349,740
$180.48 P/Share
|
|
May 11
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,262
-6.8%
|
$407,160
$180.12 P/Share
|
|
May 10
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,650
-7.85%
|
$1,067,850
$189.65 P/Share
|
|
May 10
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,846
+9.34%
|
$180,762
$47.56 P/Share
|
|
May 10
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,833
-5.22%
|
$346,437
$189.65 P/Share
|
|
May 10
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+4.96%
|
$86,151
$47.56 P/Share
|
|
May 05
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$199,000
$199.67 P/Share
|
|
May 05
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.35%
|
$31,000
$31.45 P/Share
|
|
May 05
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,290
-1.26%
|
$256,710
$199.67 P/Share
|
|
May 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,043
-1.01%
|
$208,600
$200.86 P/Share
|
|
May 03
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.2%
|
$475,932
$204.1 P/Share
|
|
Apr 13
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,958
-5.53%
|
$1,191,600
$200.0 P/Share
|
|
Apr 13
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,958
+5.16%
|
$393,228
$66.74 P/Share
|
|
Apr 13
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
6,000
-3.92%
|
$1,194,000
$199.0 P/Share
|
|
Apr 13
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+7.14%
|
$186,000
$31.45 P/Share
|
|
Apr 13
2021
|
Asaf Danziger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
97,973
-92.29%
|
$19,202,708
$196.34 P/Share
|
|
Apr 13
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
95,000
-0.71%
|
$19,285,000
$203.1 P/Share
|
|
Apr 01
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
7,928
-1.2%
|
$1,062,352
$134.12 P/Share
|
|
Mar 31
2021
|
William F Doyle Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
9,259
+1.39%
|
$1,157,375
$125.25 P/Share
|
|
Mar 23
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
3,892
-9.68%
|
$544,880
$140.0 P/Share
|
|
Mar 23
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,892
+8.83%
|
$182,924
$47.04 P/Share
|
|
Mar 09
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
3,524
-3.36%
|
$461,644
$131.09 P/Share
|
|
Mar 08
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,004
-1.92%
|
$390,520
$130.81 P/Share
|
|
Mar 08
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
765
-0.84%
|
$99,450
$130.81 P/Share
|
|
Mar 08
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,404
-3.43%
|
$312,520
$130.81 P/Share
|
|
Mar 08
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
765
-2.09%
|
$99,450
$130.81 P/Share
|
|
Mar 08
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,627
-2.45%
|
$341,510
$130.81 P/Share
|
|
Mar 05
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,918
-8.07%
|
$382,258
$131.53 P/Share
|
|
Mar 05
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
4,550
-4.06%
|
$596,050
$131.53 P/Share
|
|
Mar 05
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,987
+11.1%
|
$97,909
$7.15 P/Share
|
|
Mar 04
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
910
-2.42%
|
-
|
|
Mar 04
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
567
-1.49%
|
$77,679
$137.55 P/Share
|